4//SEC Filing
LYONS GARY A 4
Accession 0001123343-25-000006
CIK 0000914475other
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 4:14 PM ET
Size
9.2 KB
Accession
0001123343-25-000006
Insider Transaction Report
Form 4
LYONS GARY A
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-03$47.89/sh+15,000$718,350→ 135,482 total - Sale
Common Stock
2025-12-03$152.61/sh−15,000$2,289,083→ 120,482 total - Exercise/Conversion
Non-Qualified Stock Option
2025-12-03−15,000→ 0 totalExercise: $47.89Exp: 2026-05-20→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.63 to $154.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
- [F4]The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001123343
Filing Metadata
- Form type
- 4
- Filed
- Dec 3, 7:00 PM ET
- Accepted
- Dec 4, 4:14 PM ET
- Size
- 9.2 KB